Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report

In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) and second-line treatment including 5-fluorourac...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2020-01, Vol.13 (1), p.69-75
Main Authors: Arias Ron, David, Labandeira, Carmen M., Cameselle García, Soledad, García Mata, Jesús, Salgado Fernández, Mercedes
Format: Article
Language:English
Subjects:
Antibodies
appendiceal adenocarcinoma
Appendix
bevacizumab
Blood pressure
Cancer
Cancer therapies
capecitabine
Case Report
Case reports
Catheters
Chemotherapy
Colorectal cancer
Disease control
Gastrointestinal cancer
Growth factors
Hypertension
Immunotherapy
Medical imaging
Metastasis
Monoclonal antibodies
Patients
stable disease
Staphylococcus infections
Surgery
Targeted cancer therapy
Transplants & implants
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) and second-line treatment including 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus panitumumab showed inefficiency in controlling disease progression. Third-line chemotherapy combining capecitabine plus bevacizumab was started, achieving good control of the tumour growth and a minor response in the second computed tomography scan. We decided to maintain the treatment, although forced bevacizumab “breaks” were necessary due to unexpected adverse events, with the patient suffering disease progression every time bevacizumab was stopped and reaching minor response again once the antiangiogenic treatment was reintroduced. During more than 10 years after starting third-line treatment, the patient maintained good performance status and disease stability with this “up and down” management until January 2019, when a neurological adverse event during bevacizumab infusion drove us to abandon it definitely.
ISSN:1662-6575
1662-6575
DOI:10.1159/000505237